Status:

RECRUITING

A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

Lead Sponsor:

AbbVie

Conditions:

Axial Spondylarthritis (r-axSpA)

Eligibility:

All Genders

18+ years

Brief Summary

Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease primarily affecting the axial skeleton. The most frequent axSpA symptom is chronic, often inflammatory back pain that might b...

Eligibility Criteria

No eligibility criteria provided.

Key Trial Info

Start Date :

November 22 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

June 1 2026

Estimated Enrollment :

352 Patients enrolled

Trial Details

Trial ID

NCT05094128

Start Date

November 22 2021

End Date

June 1 2026

Last Update

February 2 2026

Active Locations (72)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 18 (72 locations)

1

ACURA Rheumazentrum Baden-Bade /ID# 249751

Baden-Baden, Baden-Wurttemberg, Germany, 76530

2

Heilig, Heidelberg, DE /ID# 240492

Heidelberg, Baden-Wurttemberg, Germany, 69120

3

Rheumatologische Schwerpunktpraxis /ID# 245392

Stuttgart, Baden-Wurttemberg, Germany, 70372

4

Praxis Dr. Haas /ID# 242982

Tübingen, Baden-Wurttemberg, Germany, 72072

A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting | DecenTrialz